When symptoms persist: Clozapine augmentation strategies

Schizophrenia Bulletin

Volumn 27, Issue 4, 2001, Pages 615-628

  Buckley, Peter ^a   Miller, Alexander ^a   Olsen, Jerry ^a   Garver, David ^a   Miller, Del D ^a   Csernansky, John ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Antipsychotic response; Augmentation; Clozapine; Schizophrenia; Treatment refractory

Indexed keywords

CLOZAPINE; GLYCINE RECEPTOR AGONIST; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0035697271     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a006901     Document Type: Article

References (116)

1. Treatment guidelines for the treatment of patients with schizophrenia
2. Management of treatment-resistant schizophrenia unresponsive to clozapine
3. Neuroleptic-resistant schizophrenia treated with clozapine and ECT
4. Concurrent administration of clozapine and ECT: A successful therapeutic strategy for a patient with treatment-resistant schizophrenia
5. Safety and efficacy of olanzapine versus clozapine in treatment-resistant schizophrenia in South Africa and Hungary
6. Lithium and clozapine-induced neutropenia/agranulocytosis
7. Should the administration of ECT during clozapine therapy be contraindicated?
8. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study
9. Clinical observations of 11 patients under clozapine-lithium association
10. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia
11. Treatment of delusional disorders with clozapine
12. Clozapine and risperidone: Refining and extending their use
13. Pharmacokinetics of clozapine and risperidone: A review of recent literature
14. Seizure activity in combined clozapine and ECT: A retrospective review
15. Patient response and resource management: Another view of clozapine treatment of schizophrenia
16. Serum levels of clozapine and nonclozapine in patients treated with selective serotonin reuptake inhibitors
17. Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine or valproate
18. Clozapine and metabolites: Concentrations in serum and clinical findings during treatment of chronically psychotic patients
19. Treatment issues for patients with schizophrenia who have obsessive-compulsive symptoms
20. Hoarding and clozapine-risperidone combination
21. When symptoms persist: Choosing among alternative somatic treatments for schizophrenia
22. The risks and benefits of clozapine versus chlorpromazine
23. Assessment of EPS and tardive dyskinesia in clinical trials
24. Evaluating the effects of antipsychotics on cognition in schizopohrenia
25. Treatment of special populations with the atypical antipsychotics
26. Optimizing clozapine treatment
27. Evaluation of treatment-resistant schizophrenia
28. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia
29. Treatment-resistant schizophrenia patients respond to clozapine after olanzapine nonresponse
30. Clozapine plus lamotrigine in treatment-resistant schizophrenia
31. Antipsychotic drugs: Clinical pharmacology and therapeutic use
32. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom
33. A comparison of the effects of quetiapine (Seroquel) and haloperidol in schizophrenic patients with a history of, and a demonstrated partial response to conventional antipsychotic treatment
34. Clozapine eligibility among state hospital patients
35. Combined clozapine and electroconvulsive therapy
36. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine
37. Clozapine treatment of bipolar disorder in a young adolescent
38. Seizures in two patients after the addition of lithium to a clozapine regimen
39. N-desmethylclozapine: A clozapine metabolite that suppresses haemopoiesis
40. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients
41. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia
42. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia
43. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia
44. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia
45. D-cycloserine added to clozapine for patients with schizophrenia
46. Adjunctive fluoxetine improves global function in chronic schizophrenia
47. What are the functional consequences of neurocognitive deficits in schizophrenia?
48. Olanzapine therapy and clozapine
49. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics
50. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia
51. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia
52. ECT and neuroleptics as primary treatment for schizophrenia
53. Elective combined electro-convulsive and clozapine therapy
54. Amelioration of negative symptoms in schizophrenia by glycine
55. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service
56. Increased risk of hematological side effects in psychiatric patients treated with clozapine and carbamazepine?
57. Tolerability and therapeutic effect of clozapine: A retrospective investigation of 216 patients treated with clozapine for up to 12 years
58. Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia
59. Concurrent use of clozapine and valproate in affective and psychotic disorders
60. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
61. Pharmacological treatment of schizophrenia
62. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: Implications for the therapeutics of schizophrenia
63. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis
64. Clozapine, ECT, and schizoaffective disorder, bipolar type
65. Electroconvulsive therapy and schizophrenia
66. Reversible neurotoxicity induced by a combination of clozapine and lithium: A case report
67. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome
68. The effect of long-term treatment of clozapine in schizophrenia: A retrospective study of 96 patients treated with clozapine for up to 13 years
69. Valproate acid effects on serum concentrations of clozapine and norclozapine
70. Neurobiological mechanisms of ECT: Clinical studies
71. ECT following clozapine
72. Risperidone augmentation of clozapine
73. Clinically significant interactions of psychotropic agents with antipsychotic drugs
74. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms
75. Methylphenidate for clozapine sedation
76. Risperidone and clozapine combination for the treatment of refractory schizophrenia
77. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients
78. Quetiapine and risperidone in outpatients with psychotic disorders: Results of the quest trial
79. Glutamate receptor dysfunction and schizophrenia
80. Clozapine treatment in Denmark: Concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices
81. The evolving definition of treatment resistance
82. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia
83. Effect of clozapine and high-dose glycine in treatment-resistant schizophrenia
84. Safety and effectiveness of combined ECT and clozapine in treatment resistant mania
85. High dose chlorpromazine therapy in chronic schizophrenia
86. Low dose maintenance clozapine treatment in the prophylaxis of bipolar disorder
87. Concurrent use of clozapine and divalproex sodium in the maintenance therapy of chronic schizoaffective patients: A retrospective analysis
88. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control: Preliminary findings
89. D2 and 5HT2 receptor effects of antipsychotics: Bridging basic and clinical findings using PET
90. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: Clozapine-related studies
91. The economic burden of schizophrenia: Conceptual and methodological issues, and cost estimates
92. Asterixis induced by psychotropic drug treatment
93. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
94. Combining clozapine and ECT
95. The use of ECT in the treatment of schizophrenia
96. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled study
97. Fluvoxamine augmentation for clozapine-resistant schizophrenia
98. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: An add-on double-blind, placebo-controlled study
99. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia
100. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials
101. Clozapine treatment of a non-psychotic rapid cycling bipolar disorder: A report of three cases
102. Clinical outcome in a randomized 1 year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania
103. Pharmacokinetic interactions involving clozapine
104. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
105. Treatment of schizophrenia 1999. The expert consensus guideline series
106. D-serine added to antipsychotics for the treatment of schizophrenia
107. D-serine added to clozapine for the treatment of schizophrenia
108. The effects of clozapine on aggression and substance abuse in schizophrenic patients
109. Evidence for clozapine's effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials
110. Mortality in current and former users of clozapine
111. Switching antipsychotic medications
112. Polypharmacy: Combining antipsychotic medications in the treatment of schizophrenia
113. Do anticonvulsants hinder clozapine treatment?
114. Clinical review of clozapine treatment in a state hospital
115. Risperidone in treatment-refractory schizophrenia